Exjade 125 MG Tablet for Oral Suspension

RxCUI: 616159
RxNorm name: Exjade 125 MG Tablet for Oral Suspension
Display name: Exjade 125 MG Tablet for Oral Suspension
Full name: Exjade 125 MG Tablet for Oral Suspension
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:53

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Exjade	DEFERASIROX	Novartis Pharmaceuticals Corporation	3495a70c-870c-4968-940e-8baea152cf85	2026-01-28	Boxed warning, Warnings, Adverse reactions	Exact identifier rxcui: 616159

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
3495a70c-870c-4968-940e-8baea152cf85	Exjade 125 MG Tablet for Oral Suspension	SY	49	These highlights do not include all the information needed to use EXJADE safely and effectively. See full prescribing information for EXJADE. EXJADE ® (deferasirox) tablets, for oral suspension Initial U.S. Approval: 2005	20260128
3495a70c-870c-4968-940e-8baea152cf85	EXJADE 125 MG Tablet for Oral Suspension	PSN	49	These highlights do not include all the information needed to use EXJADE safely and effectively. See full prescribing information for EXJADE. EXJADE ® (deferasirox) tablets, for oral suspension Initial U.S. Approval: 2005	20260128
3495a70c-870c-4968-940e-8baea152cf85	deferasirox 125 MG Tablet for Oral Suspension [Exjade]	SBD	49	These highlights do not include all the information needed to use EXJADE safely and effectively. See full prescribing information for EXJADE. EXJADE ® (deferasirox) tablets, for oral suspension Initial U.S. Approval: 2005	20260128